Increased plasma morphine metabolites in terminally ill cancer patients with delirium: An intra-individual comparison

Journal of Pain and Symptom Management

Volumn 23, Issue 2, 2002, Pages 107-113

  Morita, Tatsuya ^a,b   Tei, You ^a   Tsunoda, Junichi ^a   Inoue, Satoshi ^a   Chihara, Satoshi ^a  

^a Seirei Mikatabara Hospital   (Japan)

^b Seirei Mikatabara Hospital   (Japan)

Author keywords

Delirium; Morphine; Morphine 3 glucuronide; Morphine 6 glucuronide; Neoplasms; Palliative care

Indexed keywords

DRUG METABOLITE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DELIRIUM; DISTRESS SYNDROME; DRUG BLOOD LEVEL; FEMALE; HOSPICE; HUMAN; MALE; MULTIPLE ORGAN FAILURE; TERMINALLY ILL PATIENT;

ADULT; AGED; DELIRIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE DERIVATIVES; NEOPLASMS; PROSPECTIVE STUDIES; TERMINALLY ILL;

EID: 0036178344     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(01)00392-X     Document Type: Article

References (39)

1. Cognitive failure in patients with terminal cancer. A prospective study
2. Occurrences, causes, and outcome of delirium in patients with advanced cancer. A prospective study
3. Delirium in terminally ill cancer patients
4. Psychiatric morbidity in terminally ill cancer patients. A prospective study
5. The frequency and clinical course of cognitive impairment in patients with terminal cancer
6. Practice guideline for the treatment of patients with delirium
7. Palliative and terminal care
8. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient
9. Acute encephalopathy in patients with systemic cancer
10. Acute confusional states in patients with advanced cancer
11. Organic brain syndromes and opioid administration for cancer pain
12. Reversible narcotic-associated mental status impairment in patients with metastatic cancer
13. Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids
14. The cognitive effect of the administration of narcotic analgesics in patients with cancer pain
15. Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine
16. Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone
17. Chronic nausea and morphine-6-glucuronide
18. Case report. Morphine intoxication during acute reversible renal insufficiency
19. Changing pattern of agitated impaired mental status in patients with advanced cancer association with cognitive monitoring hydration, and opioid rotation
20. Opioid rotation for toxicity reduction in terminal cancer patients
21. Opioids, confusion and opioid rotation
22. Opioid hyperexcitability. The application of alternate opioid therapy
23. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone
24. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management
25. Fentanyl by continuous subcutaneous infusion for the management of cancer pain. A retrospective study
26. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients
27. Delirium and severe sedation in patients with terminal cancer
28. Morphine-6-glucuronide concentrations and opioid-related side effects. A survey in cancer patients
29. The role of morphine glucuronides in cancer pain
30. Systematic review of factors affecting the ratios of morphine and its major metabolites
31. Validity of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients
32. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients
33. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain relationship to renal function and route of administration
34. On-line clean-up system of plasma sample for simultaneous determination of morphine and its metabolites in cancer patients by high-performance liquid chromatography
35. Drug interactions in palliative care
36. Dehydration in terminally ill patients. Is it appropriate palliative care?
37. Three dimensions of the rehydration-dehydration problem in a palliative care setting